Even with access to a clinical trial, cancer patients living in the poorest neighborhoods in America have a nearly 30% greater chance of dying from their disease compared to the wealthiest patients, SWOG Cancer Research Network study results show.
Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients.
